Hilary J Longhurst, Karen Lindsay, Remy S Petersen, Lauré M Fijen, Padmalal Gurugama, David Maag, James S Butler, Mrinal Y Shah, Adele Golden, Yuanxin Xu, Carri Boiselle, Joseph D Vogel, Ahmed M Abdelhady, Michael L Maitland, Mark D McKee, Jessica Seitzer, Bo W Han, Samantha Soukamneuth, John Leonard, Laura Sepp-Lorenzino, Eliana D Clark, David Lebwohl, Danny M Cohn
BACKGROUND: Hereditary angioedema is a rare genetic disease that leads to severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 ( KLKB1 ), with the goal of lifelong control of angioedema attacks after a single dose. METHODS: In this phase 1 dose-escalation portion of a combined phase 1-2 trial of NTLA-2002 in adults with hereditary angioedema, we administered NTLA-2002 at a single dose of 25 mg, 50 mg, or 75 mg...
February 1, 2024: New England Journal of Medicine